ALISO VIEJO, Calif.—Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced financial results for the fourth quarter and full year ending Dec. 31, 2023. Net sales in the fourth quarter of 2023 of $82.4 million increased 16 percent on a reported basis, or 15 percent on a constant currency basis, compared with $71.2 million in the same period in 2022.

Net sales in 2023 of $314.7 million increased 11 percent on a reported basis, or 12 percent on a constant currency basis, compared with $282.9 million in 2022. 

“Our record fourth quarter results cap off a successful year of global execution and key milestone achievements, leaving us well positioned to execute our strategic plans as we enter into what we believe will be a transformative period for our company over the coming years,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.” 

Gross margin for the fourth quarter of 2023 was approximately 77 percent, compared with approximately 76 percent in the same period in 2022. Non-GAAP gross margin for the fourth quarter of 2023 was approximately 84 percent, compared with approximately 84 percent in the same period in 2022. Net loss in the fourth quarter of 2023 was $36.8 million, compared with a net loss of $31.5 million in the fourth quarter of 2022. 

Gross margin for 2023 was approximately 76 percent, compared with approximately 76 percent in 2022. Non-GAAP gross margin for 2023 was approximately 83 percent, compared with approximately 83 percent in 2022. Net loss in 2023 was $134.7 million, compared with a net loss of $99.2 million in 2022.

Glaukos ended the fourth quarter of 2023 with approximately $301 million in cash and cash equivalents, short-term investments and restricted cash. The company also reaffirmed 2024 net sales guidance of $350 million to $360 million.